Earnings Call · Q3 FY2022·2022-11-08

Q3 22EPS +2.82%·Rev n/aQ2 22EPS +1.28%·Rev n/aQ1 22EPS -16.67%·Rev n/aQ4 21EPS +2.56%·Rev n/a⚠ consensus missing

Royalty Pharma plc RPRX

George Grofik — SVP, Head of Investor Relations and Communications

Pablo Legorreta — CEO

Marshall Urist — Unknown (likely senior executive involved in R&D and collaborations)

Terry Coyne — Unknown (likely senior executive involved in financial/operational matters)

+0.8%1d on move date+0.2% vs SPY3d+3.8%5d+0.3%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RPRX calls or request research access.

More RPRX calls Browse calls Request research access